gemcitabine has been researched along with B-Cell Chronic Lymphocytic Leukemia in 11 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (18.18) | 18.2507 |
| 2000's | 7 (63.64) | 29.6817 |
| 2010's | 2 (18.18) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hebraud, B; Houyau, P; Laurent, G; Oberic, L; Recher, C; Suc, E; Vaillant, W; Ysebaert, L | 1 |
| Borsky, M; Brychtova, Y; Bryja, V; Collakova, J; Dzimkova, M; Hylse, O; Janovska, P; Jaskova, Z; Kasparkova, M; Kohoutek, J; Oltova, A; Paruch, K; Trbusek, M; Verner, J; Vesely, P; Zaprazna, K; Zemanova, J | 1 |
| Belch, AR; Cass, CE; Coupland, R; Graham, KA; Mackey, JR; Reiman, T; Wong, J; Young, J | 1 |
| Bufill, J; Cripe, LD; Fisher, W; Ganjoo, KN; Huh, SY; Jung, SH; McClean, J; Robertson, MJ; Williams, S | 1 |
| Nishi, R; Ueda, T; Yamauchi, T | 1 |
| Barsanti, G; Danesi, R; Del Tacca, M; Giovannetti, E; Loni, L; Mey, V; Nannizzi, S; Ricciardi, S; Savarino, G | 1 |
| Huang, P; Plunkett, W; Robertson, LE; Wright, S | 1 |
| Magagnoli, M; Pellacani, A; Tosi, P; Tura, S; Visani, G; Zinzani, PL | 1 |
| Boehrer, S; Chow, KU; Hoelzer, D; Mitrou, PS; Napieralski, S; Pourebrahim, F; Ries, J; Rummel, MJ; Stein, J; Stieler, M; Weidmann, E | 1 |
| Byrd, JC; Flinn, IW; Grever, MR; Shinn, CA; Waselenko, JK | 1 |
| Bouafia, F; Bourgeois, E; Coiffier, B; Dumontet, C; Hequet, O; Leleu, X; Morschhauser, F; Salles, G; Solal-Celigny, P; Thieblemont, C | 1 |
2 trial(s) available for gemcitabine and B-Cell Chronic Lymphocytic Leukemia
| Article | Year |
|---|---|
A phase II study of single agent gemcitabine in relapsed or refractory follicular or small lymphocytic non-Hodgkin lymphomas: a Hoosier Oncology Group Study.
Topics: Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Female; Gemcitabine; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Follicular; Male; Middle Aged | 2005 |
Gemcitabine as a single agent in the treatment of relapsed or refractory low-grade non-Hodgkin's lymphoma.
Topics: Adult; Aged; Antimetabolites; Capillary Leak Syndrome; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Female; Fever; Gemcitabine; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Leukopenia; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin; Lymphoma, T-Cell; Male; Middle Aged; Myocardial Infarction; Pulmonary Veno-Occlusive Disease; Recurrence; Renal Insufficiency; Survival Rate; Thrombocytopenia; Time Factors | 2001 |
9 other study(ies) available for gemcitabine and B-Cell Chronic Lymphocytic Leukemia
| Article | Year |
|---|---|
Clinical activity of a new regimen combining gemcitabine and alemtuzumab in high-risk relapsed/refractory chronic lymphocytic leukemia patients.
Topics: Adult; Aged; Aged, 80 and over; Alemtuzumab; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Gemcitabine; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neoplasm Staging; Recurrence; Treatment Outcome | 2015 |
Chk1 inhibition significantly potentiates activity of nucleoside analogs in TP53-mutated B-lymphoid cells.
Topics: Animals; Apoptosis; B-Lymphocytes; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cell Survival; Checkpoint Kinase 1; Cytarabine; Deoxycytidine; Drug Screening Assays, Antitumor; Gemcitabine; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Mice; Mice, Transgenic; Mitosis; Mutation; Nucleosides; Pyrazoles; Pyrimidines; Signal Transduction; Tumor Suppressor Protein p53; Vidarabine | 2016 |
Mechanisms of resistance to nucleoside analogue chemotherapy in mantle cell lymphoma: a molecular case study.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Case-Control Studies; Deoxycytidine; DNA (Cytosine-5-)-Methyltransferases; Drug Resistance, Neoplasm; Gemcitabine; Gene Expression Profiling; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Mantle-Cell; Male; Middle Aged; Neoplasm Proteins; Ribonucleotide Reductases; Vidarabine | 2002 |
A new, simple method for quantifying gemcitabine triphosphate in cancer cells using isocratic high-performance liquid chromatography.
Topics: Antimetabolites, Antineoplastic; Arabinofuranosylcytosine Triphosphate; Chromatography, High Pressure Liquid; Cytarabine; Deoxycytidine; Gemcitabine; HL-60 Cells; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Sensitivity and Specificity | 2006 |
Cytotoxic activity of gemcitabine and correlation with expression profile of drug-related genes in human lymphoid cells.
Topics: 5'-Nucleotidase; Aged; Antigens, CD; Antimetabolites, Antineoplastic; Apoptosis; Cell Cycle; Cell Proliferation; Cell Survival; Deoxycytidine; Deoxycytidine Kinase; Dose-Response Relationship, Drug; Equilibrative Nucleoside Transporter 1; Female; Gemcitabine; Gene Expression Profiling; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Humans; Immunophenotyping; Jurkat Cells; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Patient Selection; Predictive Value of Tests; Reproducibility of Results; Reverse Transcriptase Polymerase Chain Reaction; Ribonucleoside Diphosphate Reductase; RNA, Messenger; Treatment Outcome; Tumor Cells, Cultured; Tumor Suppressor Proteins | 2007 |
High molecular weight DNA fragmentation: a critical event in nucleoside analogue-induced apoptosis in leukemia cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Aphidicolin; Apoptosis; Chelating Agents; Deoxycytidine; DNA Fragmentation; DNA, Neoplasm; Egtazic Acid; Enzyme Inhibitors; Gemcitabine; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Molecular Weight; Tumor Cells, Cultured; Vidarabine | 1995 |
In vitro study of the combination gemcitabine + fludarabine on freshly isolated chronic lymphocytic leukemia cells.
Topics: Antimetabolites, Antineoplastic; Apoptosis; Deoxycytidine; DNA, Neoplasm; Drug Synergism; Gemcitabine; Gene Expression Regulation, Leukemic; Genes, bcl-2; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Neoplasm Proteins; Neoplastic Stem Cells; Proto-Oncogene Proteins c-bcl-2; Vidarabine | 1999 |
Induction of apoptosis using 2',2' difluorodeoxycytidine (gemcitabine) in combination with antimetabolites or anthracyclines on malignant lymphatic and myeloid cells. Antagonism or synergism depends on incubation schedule and origin of neoplastic cells.
Topics: Anthracyclines; Antimetabolites, Antineoplastic; Apoptosis; Deoxycytidine; Drug Therapy, Combination; Gemcitabine; HL-60 Cells; Humans; Jurkat Cells; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphatic System; Lymphoma; Myeloid Cells | 2000 |
Gemcitabine demonstrates in vitro activity against human B-cell chronic lymphocytic leukemia.
Topics: Antimetabolites, Antineoplastic; Apoptosis; bcl-2-Associated X Protein; Deoxycytidine; Gemcitabine; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; Tumor Suppressor Protein p53 | 2001 |